What Ionis Pharmaceuticals (IONS)'s Phase 3 Wins Mean For Shareholders

• Ionis Pharmaceuticals and partners reported positive Phase 3 results in 2026 for two RNA-targeted medicines, ulefnersen in FUS-ALS and sefaxersen in primary IgA nephropathy, each meeting its primary endpoint with favourable safety profiles.
• These late-stage outcomes show Ionis converting its antisense platform into potential commercial therapies across both rare neurodegenerative disease and kidney disease, which could influence how its R&D-heavy model translates into future product and royalty streams.
• Next, the focus turns to how Ionis Pharmaceuticals' investment narrative could evolve as ulefnersen's ALS data reframes late-stage pipeline risk.

Scan beyond Ionis Pharmaceuticals and see how other RNA and biotech players are positioned by reviewing our hand picked 17 high quality undiscovered gems that are gearing up around similar late stage readouts.

Ionis Pharmaceuticals Investment Narrative Recap

For Ionis Pharmaceuticals, the core belief is that its RNA platform can keep producing medicines that turn into meaningful product and royalty streams. You would be backing a business that is still loss making, with net income of a loss of US$565.2 million on US$874.1 million of revenue, yet leaning on new launches and late stage programs to shift toward profitability.

The biggest near term swing factor remains execution on upcoming approvals and launches, such as donidalorsen and olezarsen, as Ionis leans on a handful of high impact assets. Recent ulefnersen and sefaxersen data helps diversify perceived pipeline risk, but does not remove pricing pressure, partner dependence, or the chance of lumpy revenues if key regulatory timelines slip.

The ulefnersen Phase 3 FUSION readout looks most relevant for near term catalysts because it ties directly into the existing neurology footprint and Ionis Pharmaceuticals commercial ALS presence with Qalsody. Positive functional and survival data in genetically confirmed FUS ALS reinforces the idea that the antisense platform can extend into adjacent neurodegenerative niches.

Operationally, that single rare disease program will not solve broader issues such as pricing negotiations for larger indications, reliance on partners for ex US markets, or the current share price drawdown, with the stock down 42.4% year to date as of late September 2026. It does, however, give management another late stage asset to advance toward potential filings, which could matter for how investors weigh concentration risk in donidalorsen and olezarsen over the next few years.

Ionis Pharmaceuticals' current analyst story points to revenues of US$2.3b and earnings of US$222.2 million by 2029, built on forecast top line growth of 37.1% a year and an earnings swing of about US$787.4 million from a loss of US$565.2 million today to the projected profit level.

Uncover how Ionis Pharmaceuticals' fair value indicates a 92% potential upside to its current price before the market closes the gap.

Exploring Other Perspectives

One alternate view puts far more weight on Ionis Pharmaceuticals' earnings potential than on pipeline concentration risk. Before this ALS and IgAN news, the most optimistic analysts were pencilling in about US$2.9b of revenue and US$687.6 million of earnings by 2029. That is a much richer story than consensus, and it may shift again as fresh data filters through.

Explore 3 other Ionis Pharmaceuticals fair value estimates, including one that suggests a potential upside of up to 554% from the current price.

Reach Your Own Conclusion

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Ionis Pharmaceuticals research is our analysis highlighting 2 key rewards that could impact your investment decision.
• See our latest analysis for Ionis Pharmaceuticals. The report includes a comprehensive fundamental analysis summarized in a single visual, the Snowflake, making it easy to evaluate Ionis Pharmaceuticals' overall financial health at a glance.

Looking For More Investment Ideas Beyond Ionis Pharmaceuticals?

If the Ionis Pharmaceuticals story has you thinking about where else late stage pipelines, balance sheets, or income potential might line up in your favor, broaden your shortlist using the Simply Wall St Screener before committing fresh capital.

• If you are hunting for potential mispricing, start with 31 high quality undervalued stocks that combine stronger fundamentals with what may be more modest expectations baked into current prices.
• For readers who care most about resilience, filter for 32 resilient stocks with low risk scores that score well on financial durability and business risk metrics.
• If cash generation and balance sheet strength matter most to you, focus on our list of solid balance sheet and fundamentals (25 results) to see which businesses currently meet that hurdle.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com